Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens

Human Pathology

Volumn 35, Issue 9, 2004, Pages 1070-1082

  Brunt, Elizabeth M ^a,b,c   Neuschwander Tetri, Brent A ^a,c   Oliver, Dana ^c   Wehmeier, Kent R ^c   Bacon, Bruce R ^a,c  

^a Saint Louis University   (United States)

^b Department of Pathology ^*  (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alanine aminotransferase; alkaline phosphatase; ALP; ALT; aspartate aminotransferase; AST; BMI; body mass index; diabetes mellitus; DM; gamma glutamyl transpeptidase; GGT; histologic criteria; IGT; insulin resistance; nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY LIVER; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MEASUREMENT; NONALCOHOLIC FATTY LIVER; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

BIOPSY; BLOOD GLUCOSE; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED; TRANSCRIPTION FACTORS;

EID: 4444290464     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.04.017     Document Type: Article

References (39)

1. Das U.N. Is metabolic syndrome X an inflammatory condition? Exp Biol Med. 227:2002;989-997
2. Youssef W.I., McCullough A.J. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis. 13:2002;17-30
3. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome Further evidence for an etiologic association. Hepatology. 35:2002;367-372
4. Chitturi S., Farrell G.C. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 21:2001;27-41
5. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 35:2002;373-379
6. Day C.P. Pathogenesis of steatohepatitis. Balliere's Best Pract Res Clin Gastroenterol. 16:2002;663-678
7. Day C.P., Saksena S. Nonalcoholic steatohepatitis Definitions and pathogenesis. J Gastroenterol Hepatol. 17:2002;S377-S384
8. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis Summary of an AASLD single topic conference. Hepatology. 37:2003;1202-1219
9. Neuschwander-Tetri B.A. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 4:2002;31-36
10. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterolgy. 123:2002;1705-1725
11. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease A feature of the metabolic syndrome. Diabetes. 50:2001;1844-1850
12. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 37:2003;917-923
13. Dixon J.B., Bhatal P.S., O'Brien P.E. Nonalcoholic fatty liver disease Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 121:2001;91-100
14. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improvement in nonoalcholic steatohepatitis following 48 weeks of treatment with the PPARγ ligand rosiglitazone. Hepatology. 38:2003;1008-1017
15. Neuschwander-Tetri B.A., Brunt E.M., Bacon B.R., et al. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with the PPARγ agonist rosiglitazone. [abstract] Hepatology. 36:2002;379A
16. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 38:2003;434-440
17. Health NIH. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults The evidence report. Obes Res. 6:1998;51S-209S
18. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis A proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:1999;2467-2474
19. Brunt E.M., Olynyk J.K., Britton R.S., et al. Histological evaluation of iron in liver biopsies Relationship to HFE mutations. Am J Gastroenterol. 95:2000;1788-1793
20. Group TFMCS. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:1994;15-20
21. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology. 118:2000;1117-1123
22. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 34:2002;255-262
23. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of non-alcoholic steatohepatitis From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123:2002;134-140
24. Shimada M., Hashimoto E., Taniai M., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 37:2002;154-160
25. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 35:2002;1485-1493
26. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis Clinical characterization and risk factors for underlying disease. Hepatology. 29:1999;664-669
27. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:1980;434-438
28. Skelly M.M., James P.D., Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 35:2001;195-199
29. National Cholesterol Education Program Expert Panel. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
30. Silverman J.F., O'Brien K.F., Long S., et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 85:1990;1349-1355
31. Marceau P., Biron S., Hould F.S., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 84:1999;1513-1517
32. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease A spectrum of clinical and pathological severity. Gastroenterology. 116:1999;1413-1419
33. Younossi Z.M., Gramlich T., Liu Y.C., et al. Nonalcoholic fatty liver disease Assessment of variability in pathologic interpretations. Mod Pathol. 11:1998;560-565
34. Dixon J.B., O'Brien P.E., Bhatal P.S. A wider view on diagnostic criteria of nonalcoholic steatohepatitis. [reply] Gastroenterology. 122:2002;841-842
35. Brunt E.M., Ramrakhiani S., Cordes B.G., et al. Concurrence of histologic features of steathepatitis with other forms of chronic liver disease. Mod Pathol. 16:2003;49-56
36. Clouston A.D., Powell E.E. Interaction of non-alcoholic fatty liver disease with other liver diseases. Balliere's Best Pract Res Clin Gastroenterol. 16:2002;767-781
37. Burt A.D., Mutton A., Day C.P. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Liver Dis. 15:1998;246-258
38. Brunt E.M. Nonalcoholic steatohepatitis Definition and pathology. Semin Liver Dis. 21:2001;3-16
39. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 30:1999;1356-1362